[Abstract Only] Randomized Trial: SGLT2 Inhibitor Reduces Adverse Renal Events in Patients with Type 2 Diabetes and Nephropathy

14 Jun, 2019 | 06:49h | UTC

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation – CREDENCE – American College of Cardiology (free)

 

Join our WhatsApp group

Free Updates in All Specialties!

A daily update on the latest medical news, practice-changing trials and guidelines

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •